Showing 841-850 of 1211 results for "".
- Ocular Therapeutix to Present Preclinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/ocular-therapeutix-to-present-preclinical-and-clinical-data-at-the-2022-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2480797/Ocular Therapeutix announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting being held May 1-4 in Denver, Colorado and May 11-12 virtually. “At this year’s annual meeting, we are thrilled to be presenting c
- Harvard Eye Associates Surgeons Implant the First AccuraSee IOPCL to Treat Macular Degenerationhttps://modernod.com/news/harvard-eye-associates-surgeons-implant-the-first-accurasee-iopcl-to-treat-macular-degeneration/2480721/Harvard Eye Associates reported that its surgeons have implanted the first AccuraSee Intraocular Pseudophakic Contact Lens (IOPCL) to improve near vision in patients with macular degeneration. The AccuraSee lens implant is placed to help magnify images and allow patients to use parts of
- New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with Tepezza Comparable with Clinical Trial Observationshttps://modernod.com/news/new-post-marketing-safety-analysis-shows-rate-of-hearing-related-events-associated-with-tepezza-comparable-with-clinical-trial-observations/2480647/Horizon Therapeutics announced results from a new post-marketing safety analysis of hearing events associated with Tepezza for the treatment of Thyroid Eye Disease (TED). These findings, along with data on the sustainability of response to Tepezza, were presented at the 48th
- Ocular Therapeutix Gains New Indication for Dextenza to Include Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-nabs-new-indication-for-dextenza-to-include-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2480340/Ocular Therapeutix announced the FDA has approved its supplemental new drug application (sNDA) to broaden the Dextenza label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the approval, Dextenza is the first, FDA-approve
- Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/palatin-announces-two-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479093/Palatin Technologies announced two presentations of the company’s melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021. The
- EyeCare Associates of East Texas Announces Partnership With Private Equity Firm EyeCare Partnershttps://modernod.com/news/eyecare-associates-of-east-texas-announces-partnership-with-private-equity-firm-eyecare-partners/2478721/Brown Gibbons Lang & Company (BGL) has announced a new partnership between EyeCare Associates of East Texas (ECA) and EyeCare Partners (ECP) resulting in the addition of ECA’s four Texas clinics to ECP’s national ne
- Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGDhttps://modernod.com/news/bausch-health-initiates-second-phase-3-study-for-nov03-investigational-treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction/2478590/Bausch + Lomb announced the initiation of the second of two phase 3 studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meib
- Neuro-Optometric Rehabilitation Association Announces Appointments of New Executive and Advisory Board Officershttps://modernod.com/news/neuro-optometric-rehabilitation-association-announces-appointments-of-new-executive-and-advisory-board-officers/2478297/The Neuro-Optometric Rehabilitation Association (NORA) announced the appointments of its new executive and advisory board members. DeAnn Fitzgerald, OD, assumes the position of President, succeeding Susan Daniel, OD, who now joins the NORA Advisory Board. Dr. Fitzgerald has been providing
- Roche’s Actemra/RoActemra Fails in Severe COVID-19-Associated Pneumonia Studyhttps://modernod.com/news/roches-actemra-roactemra-fails-in-severe-covid-19-associated-pneumonia-study/2478097/Roche said that a phase 3 study investigating Actemra/RoActemra (tocilizumab) in hospitalized adults with severe COVID-19-associated pneumonia failed to meet its primary endpoint of improved clinical status. The company launched the COVACTA trial in March in order to investigate the anti-IL-6 rec
- Ocugen Granted FDA Orphan Drug Designation for Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-rho-mutation-associated-retinal-degenerative-disease/2478081/Ocugen announced the FDA granted the third orphan drug designation (ODD) for OCU400 in the treatment of RHO mutation-associated retinal degeneration. The RHO mutation is part of the retinitis pigmentosa (RP) group of rare, genetic disorders that involve a breakdown and loss of